Irritable Bowel Syndrome Treatment Market Size is expected to reach at USD 4.7 Billion by 2030, registering a CAGR of 9.5%, Owing to Increasing Incidences of Gastrointestinal Disorders
October 03, 2022 09:48 ET
|
Acumen Research and Consulting
LOS ANGELES, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Global Irritable Bowel Syndrome Treatment Market Size accounted for USD 2.1 Billion in 2021 and is projected to achieve a market size of USD 4.7...
metaMe Health partners with Launchit Ventures to market Regulora, an FDA-cleared Prescription Digital Therapeutic for adults with IBS, in Canada
September 29, 2022 09:00 ET
|
metaMe Health, Inc.
HAMILTON, Ontario and CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Launchit Ventures, Inc., a HealthTech solutions provider and global commercialization partner developing new technology-led business...
Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
August 30, 2022 08:19 ET
|
Biomerica, Inc.
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development...
Metacrine Reports Second-Quarter 2022 Results
August 09, 2022 16:05 ET
|
Metacrine, Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal...
Digestive Health Products Market to reach USD 79.2 Billion by 2030 growing at a CAGR of 8%: Straits Research
May 30, 2022 14:15 ET
|
Straits Research
New York, United States, May 30, 2022 (GLOBE NEWSWIRE) -- Digestive system health products are supplements that help people's digestive health by improving gut function. Foods, functional foods, and...
Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021
April 14, 2022 08:37 ET
|
Biomerica, Inc.
Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome
February 08, 2022 06:39 ET
|
Biomerica, Inc.
InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021
January 13, 2022 08:19 ET
|
Biomerica, Inc.
Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon...
Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million
December 16, 2021 08:19 ET
|
Biomerica, Inc.
InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
Biomerica Receives Notice of Allowance from Canadian Patent Office for Patent Covering Irritable Bowel Syndrome (IBS) Food Sensitivity Testing & Treatment
November 04, 2021 06:39 ET
|
Biomerica, Inc.
Studies show that 13-20% of Canadians suffer from IBS at any given time1. The lifetime risk for a Canadian to develop IBS is 30%1. IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....